Learn more

HANDOK INC

Overview
  • Total Patents
    57
  • GoodIP Patent Rank
    36,312
  • Filing trend
    ⇩ 90.0%
About

HANDOK INC has a total of 57 patent applications. It decreased the IP activity by 90.0%. Its first patent ever was published in 2006. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, medical technology and organic fine chemistry are OBSTETRICS & GYNECOLOGY HOSPITAL FUDAN UNIV, DONGGUAN MATHEMATICAL ENGINEERING ACADEMY OF CHINESE MEDICINE GUANGZHOU UNIVERSITY OF CHINESE MEDICI and ALTAIR INSTR INC.

Patent filings per year

Chart showing HANDOK INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Jang Woo Ick 11
#2 Song Seung Woo 9
#3 Pai Jin Keon 8
#4 Ahn Koo Hyeon 7
#5 Hwang In Je 7
#6 Jang Hae Won 7
#7 Hong Hye-Suk 7
#8 Pai Jin-Keon 7
#9 Song Seung-Woo 7
#10 Kim Dong-Wook 7

Latest patents

Publication Filing date Title
HK1258248A1 Preparation for relieving hangover comprising curcumin
US2017204101A1 Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
CN108283664A Alleviation containing curcumin, which is still drank after a night, uses preparation
KR20170091333A Tablet containing teneligliptin and sulfonylurea
KR101526825B1 Pharmaceutical Compositions for The Treatment of Diabetes
KR20160035507A Catheter and manufacturing method thereof
KR20160035506A Catheter and manufacturing method thereof
KR20140100451A Catheter for denervation
KR20150115448A Preparation for relieving hangover comprising Curcumin
WO2015056851A1 Orally disintegrating tablet containing aripiprazole and method for preparing same
KR20150101290A Catheter for denervation
MX2015010090A Nerve block catheter.
AU2013402175A1 Novel triazolopyrazine derivative and use thereof
WO2014025199A2 Staphylococcal enterotoxin-derived superantigen mutant, fusion protein in which target-specific polypeptides are connected to the mutant and use thereof
WO2014025198A2 Lfa3 mutant, fusion protein in which target-specific polypeptides are connected to the mutant or lfa3 cd2 binding region, and use thereof
KR20140021485A Superantigen derived from staphylococcal enterotoxin and fusion protein comprising target specific polypeptide linked thereto and use thereof
KR20140021799A Lfa3 variant and fusion protein comprising target specific polypeptide linked to the lfa3 variant or lfa3 cd2 binding region and use thereof
KR20140131205A Pharmaceutical composition containing highly water-soluble drug for sustained release
KR20140104198A Catheter for denervation
KR20140100168A Catheter for denervation